TGFB1 and myocardial infarction: Inhibition of TGFβ signaling by an orally administered small-molecule inhibitor of TGFβR1 (GW788388) starting on the day of experimentally induced MI (non-reperfusion) in rats results in attenuated systolic dysfunction and left ventricular remodeling concomitant with a reduced number of α-smooth muscle actin-positive cells in the cardiac interstitium and reduced collagen I expression in the non-infarct zone [108].